Gates Package — page 260
of 1375 pages · Bates Q4 2021
← p.259 p.261 → · this page in the original PDF · package
NIH-Funded ACTIV/ACTIV-Associated Clinical Trials I National
Institutes of Health (NIH)
B®
nih.gow/activinin-funded-activ/activ-associated-clinical-trials
NIH) National Institutes of Health
Turning Discovery Into Health
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
February 11, 2021
New/
Estimated
Company
Therapeutic
Class
Administration
Repurposed
End Date
ACTIV-1 Inpatient
BMS
Orencia
Immune
Intravenous
Repurposed
4 2021
(abatacept)
Modulator
Janssen
Remicade
Immune
Intravenous
Repurposed
Q4 2021
(Infliximab)
Modulator
AbbVie
Cenicriviroc
Immune
Oral
New
Q4 2021
Modulator
ACTIV-2 Outpatient
AstraZeneca
AZD7442
Monoclonal
Intramuscular
New
Q4 2021
Antibody
Cocktail
AstraZeneca
AZD7442
Monoclonal
Intravenous
New
Q4 2021
Antibody
Cocktail
Brii Biosciences
Brii-196 & Brii-
Monoclonal
Intravenous
New
Q4 2021
Antibody
Cocktail
Eli Lilly
LY-CoV-555
Monoclonal
Intravenous
New
Q1 2021
Antibody Single
Sagent
Camostat
Antiviral
Oral
Repurposed
Mesylate
Synairgen
SNGO01 IFN-
Immune
Inhaled
Repurposed
4 2021
beta
Modulator
ACTIV-3 Inpatient
1/3
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/gates/260
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| gates:exh:00153 | — | attachment | 260 |